A5069477617- Renal and related cancers
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Genomics and Rare Diseases
- Pediatric Urology and Nephrology Studies
- RNA modifications and cancer
- Ethics and Legal Issues in Pediatric Healthcare
- Acute Lymphoblastic Leukemia research
- Congenital Diaphragmatic Hernia Studies
- Cancer-related gene regulation
- Pancreatic and Hepatic Oncology Research
- Sarcoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Tracheal and airway disorders
- Lung Cancer Research Studies
- Genomic variations and chromosomal abnormalities
- RNA and protein synthesis mechanisms
- Cancer survivorship and care
- Barrier Structure and Function Studies
- Chromatin Remodeling and Cancer
- Tumors and Oncological Cases
- Polyomavirus and related diseases
Cook Children's Medical Center
2010-2025
Palmetto Hematology Oncology
2022
St. Jude Children's Research Hospital
2010
University Medical Center New Orleans
1999
Tulane University
1999
Every year, approximately 600 infants, children, and adolescents are diagnosed with renal cancer in the United States. In addition to Wilms tumor (WT), which accounts for about 80% of all pediatric cancers, clear cell sarcoma kidney, carcinoma, malignant rhabdoid tumor, as well more rare cancers (other sarcomas, carcinomas, lymphoma) benign tumors can originate within kidney. WT itself be divided into favorable histology (FHWT), a 5-year overall survival (OS) exceeding 90%, anaplastic...
Objective: To evaluate age, TNW, or tumor diameter (TD) as continuous prognostic variables for outcomes in early stage FHWT after accounting biology and treatment. Summary of Background Data: Patient age (< 2 vs. ≥ years) nephrectomy weight (TNW; < 550g 550 grams) have been used to risk stratify children with I favorable histology Wilms (FHWT) on Children’s Oncology Group (COG) studies select patients omission chemotherapy. Methods: Included had II per central review were treated only,...
Background Stage I epithelial‐predominant favorable‐histology Wilms tumors (EFHWTs) have long been suspected to an excellent outcome. This study investigates the clinical and pathologic features of patients with stage EFHWTs better evaluate potential for a reduction chemotherapy its associated toxicity. Methods All registered in Children's Oncology Group (COG) AREN03B2 between 2006 2017 were identified. defined as at least 66% epithelial differentiation, regardless degree differentiation....
The application of molecular tumor profiles in clinical decision making remains a challenge. To aid the interpretation complex biomarkers, boards (MTBs) have been established worldwide. In present study, we show that multidisciplinary approach is essential to success MTBs. Our MTB, consisting pediatric oncologists, pathologists, and pharmacists, evaluated 115 cases diagnosed between March 2016 September 2021. If targetable mutations were identified, pharmacists aided evaluation treatment...
Clinical variant analysis pipelines likely have poor sensitivity to the effects on splicing from variants beyond 10 20 bases of exon-intron boundaries. Here, we demonstrate value SpliceAI inform curation rare previously classified as benign/likely benign (B/LB) under current guidelines.
PURPOSE To evaluate the relative diagnostic yield of clinical germline genomic tests in a diverse pediatric cancer population. PATIENTS AND METHODS The KidsCanSeq study enrolled patients across six sites Texas. Germline analysis included both exome sequencing and therapy-focused gene panel. results were categorized by participants demographics, presence pathogenic or likely (P/LP) variants, variants uncertain significance (VUS) predisposition genes (CPGs). Pediatric actionable CPGs defined...
Purpose/Objectives: To explore an association between sleep quality in children and adolescents undergoing therapy for acute lymphoblastic leukemia (ALL) polymorphisms two proinflammatory cytokines, interleukin-6 (IL-6) tumor necrosis factor (TNF). Design: Retrospective exploratory analysis using data from a multi-institutional prospective study comparing objective measures by actigraphy over 10 days with retrospective genotyping of IL-6 (-174GC) TNF (-308GA). Setting: Pediatric oncology...
The potential of circulating tumor DNA (ctDNA) analysis to serve as a real-time "liquid biopsy" for children with central nervous system (CNS) and non-CNS solid tumors remains be fully elucidated. We conducted study investigate the feasibility clinical utility ctDNA sequencing in pediatric patients enrolled on an institutional genomics trial. A total 240 had profiling performed during period. Plasma samples were collected at enrollment from 217 then longitudinally subset patients. Successful...
Access to genomic sequencing (GS) and resulting recommendations have not been well described in pediatric oncology. GS results may provide a cancer predisposition syndrome (CPS) diagnosis that warrants screening specialist visits beyond treatment, including testing or surveillance for family members. The Texas KidsCanSeq (KCS) Study evaluated implementation of diverse oncology population. We conducted semi-structured interviews (n = 20) explore experiences KCS patients' families around...
The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines.
Histiocytic sarcoma (HS) is a rare neoplasm with no known cause. This characterized by morphology similar to that demonstrated mature tissue histiocytes and mostly afflicts adults. HSs typically have poor prognosis due rapidly progressive clinical course. Our patient’s case was unique its presentation four years after completion of treatment for B-cell acute lymphoblastic leukemia. The patient experienced progression initial therapy HS. With dual immunotherapy radiation, however, the has...
Abstract Introduction The prognostic impact of positive lymph nodes (LN+) and/or singular loss heterozygosity (LOH) 1p or 16q were assessed in children with stage III favorable histology Wilms tumor (FHWT) enrolled on AREN0532 AREN03B2 alone. Patients and Methods A total 635 FHWT vincristine/dactinomycin/doxorubicin (DD4A)–treated patients met inclusion criteria. Event‐free survival (EFS) overall are reported by LN sampling, status, LOH 1p, 16q, a combination status LOH. unknown combined...
Immunotherapy has emerged as a promising treatment approach in oncology, it is specifically designed to boost the strength and accuracy of immune system, allowing target tumor cells but spare non-tumor tissue. This not only demonstrates potential for improved clinical outcomes may also be associated with fewer adverse effects compared traditional therapies. Despite its early success, application immunotherapy largely been limited adult cancer patients, slow adoption noted pediatric patients....
Context.— The distinction between well-differentiated epithelial favorable-histology Wilms tumor (EFHWT) and metanephric adenoma (MA) in children has historically been determined by the required absence of both a fibrous pseudocapsule mitotic activity MA. More recently these features have allowed adult Mutations exon 15 BRAF gene are reported up to 88% MAs but not EFHWTs lacking MA features. Objective.— To clarify pathologic molecular used distinguish pediatric EFHWT. Design.— Stage I tumors...
Our study aims to report the prevalence of potentially actionable oncogenic variants in a sample pediatric tumors from single institution using reference laboratory for tumor profiling. We investigated genomic alterations and immunotherapy biomarkers such mutation burden, microsatellite instability, programmed death-ligand 1. Patients treated Cook Children's Health Care System who had profiling performed by Foundation Medicine between January 1, 2013, May 2019, were included. Demographic...